Novo Nordisk Shares Face Mounting Challenges Amid Supply and Competitive Pressures

Novo Nordisk finds itself navigating one of its most challenging periods in the stock market for years. The pharmaceutical company, once a dominant star in the obesity treatment sector, has seen its valuation erode significantly as competitor Eli Lilly captures market attention. A confluence of regulatory risks, supply chain concerns, and pipeline developments is now creating a complex pressure point for the firm.

A recent warning letter from the U.S. Food and Drug Administration (FDA) has applied the most immediate downward pressure on the share price. The regulatory action targets a production facility in Indiana operated by contract manufacturer Catalent, a critical link in Novo Nordisk’s supply chain Read more...